When:
Tuesday, Dec 04, 2018 8:00a -
Thursday, Dec 06, 2018 3:15p

Where:
Hilton Boston Back Bay
40 Dalton Street
Boston, Massachusetts 02115

Admission:
$499

Categories:
Lectures & Conferences

Event website:
http://go.evvnt.com/260431-0?pid=5248

As many oncolytic viruses progress through the clinical pipelines, drug developers need to ensure that their therapies are safe, efficacious and commercially viable. Make sure you stay ahead of the game and join Oncolytic Virotherapy Summit, where you will have an opportunity to pick the brains of 100+ senior industry peers and tackle your challenges in discovery, clinical development, manufacturing and regulations of oncolytic virotherapy.


This year we will be incorporating commercial insights from companies such as Merck, Virogen, Sagetis, Lokon Pharma, Replimmune, Western Oncolytics, DNAtrix and many more, which will allow you to learn from their case studies and improve your development strategies. Participate in the interactive roundtable and workshops to build strategies that maximise success in the clinic and commercially.


Sounds interesting? Find out more – get free event brochure here: http://bit.ly/2vsAIRC


URLs:
Website: https://go.evvnt.com/260431-2?pid=5248
Tickets: https://go.evvnt.com/260431-3?pid=5248


Price:
Conference + 2 Workshops (Drug Developers): GBP 3797.0
Conference + 1 Workshop (Drug Developers): GBP 3298.0
Conference Only (Drug Developers): GBP 2799.0
Workshops (Each) (Drug Developers): GBP 599.0
Conference + 2 Workshops (Academic): GBP 2397.0
Conference + 1 Workshop (Academic): GBP 1998.0
Conference Only (Academic): GBP 1599.0
Workshops (Each) (Academic): GBP 499.0
Conference + 2 Workshops (Vendor & Solution Providers): GBP 4297.0
Conference + 1 Workshop (Vendor & Solution Providers): GBP 3698.0


Speakers: Grant McFadden, Center Director & Professor, Biodesign Center for Immunotherapy, ASU, Masataka Suzuki, Assistant Professor, Baylor College of Medicine, Brad Nelson, Director, Deeley Research Centre BC Cancer Agency, Frank Tufaro, CEO, DNAtrix, Antonio Chiocca, Professor, Harvard Medical School, Faris Farassati, Associate Professor, University of Kansas Medical School, Angelica Loskog, CEO, Lokon Pharma, Rachel Altura, Senior Medical Director, Merck & Co., Christophe Queva, Chief Scientific Officer, Oncorus, Steven Potts, CEO, OncoMyx, Robert Coffin, CEO, Replimmune, Anna Cascante, Head of R&D, Sagetis Biotech, Magnus Jaderberg, CMO, Targovax, Min Liang, CSO, TOT biopharma, José Manuel Otero, Vice President, CMC & Manufacturing, Turnstone Biologics, Daniel Katzman, Chief Executive Officer, Unleash Immuno Oncolytics, Stephen Thorne, Chief Scientific Officer, Western Oncolytics, William Jia, Chief Scientific Officer, Virogen

Share this event

Add to:

04/12/2018 08:00:00 06/12/2018 15:15:00 15 4th Oncolytic Virotherapy Summit 2018 <p>As many oncolytic viruses progress through the clinical pipelines, drug developers need to ensure that their therapies are safe, efficacious and commercially viable. Make sure you stay ahead of ... Hilton Boston Back Bay, Boston, Massachusetts 02115 Organizer Organizer e-mail false DD/MM/YYYY Reddit